J&J carries ICOTYDE momentum into Q3 earnings
Alpha Vantage · TradingKey · · AI-summarised by FinFlash
Johnson & Johnson heads into its Q3 earnings report with momentum from strong Q2 results, raised 2026 sales guidance and robust two-year ICOTYDE psoriasis data. Oncology, neuroscience and MedTech growth is offsetting STELARA biosimilar competition, though talc litigation remains a risk. Analysts hold 16 Buy, 6 Hold and 1 Sell ratings, with a $279.64 target implying 7.0% upside from $261.44.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.